Dynavax Technologies Corporation Share Price DVAX

$15.5

Last updated on February 9, 2026 at 12:00 am IST

$₹

This instrument is not available for trading on the INDmoney app on 9 Feb 2026

Check the interactive Dynavax Technologies Corporation Stock chart to analyse performance

Dynavax Technologies Corporation Key Stats

Check Dynavax Technologies Corporation key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$15.5
Open	$15.49
Market Capitalization	$1.8B
Today's Volume	$7.1M
Revenue TTM	$330.5M
EBITDA	$24.2M
Earnings Per Share (EPS)	$-0.37
Profit Margin	-13.13%
Quarterly Earnings Growth YOY	0.69%
Return On Equity TTM	-7.14%

Global Institutional Holdings in Dynavax Technologies Corporation

Name
Holdings %
Name
Holdings %
Deep Track Capital, LP
15.17%
BlackRock Inc
14.71%
Vanguard Group Inc
7.19%
State Street Corp
5.45%
Chicago Capital LLC
4.46%
Dimensional Fund Advisors, Inc.
3.11%

Analyst Recommendation on Dynavax Technologies Corporation Stock

Rating

Trend

Buy

83%Buy

16%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Dynavax Technologies Corporation(by analysts ranked 0 to 5 stars)

Dynavax Technologies Corporation Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$35.2M	↑ 329.6%
Net Income	$-152.6M	↓ 3.96%
Net Profit Margin	-433.29%	↑ 1504.98%

	FY20	Y/Y Change
Revenue	$46.6M	↑ 32.18%
Net Income	$-75.2M	↓ 50.69%
Net Profit Margin	-161.63%	↑ 271.66%

	FY21	Y/Y Change
Revenue	$439.4M	↑ 844.0%
Net Income	$76.7M	↓ 201.96%
Net Profit Margin	17.46%	↑ 179.09%

	FY22	Y/Y Change
Revenue	$722.7M	↑ 64.45%
Net Income	$293.2M	↑ 282.15%
Net Profit Margin	40.56%	↑ 23.1%

	FY23	Y/Y Change
Revenue	$232.3M	↓ 67.86%
Net Income	$-6.4M	↓ 102.18%
Net Profit Margin	-2.75%	↓ 43.31%

	FY24	Y/Y Change
Revenue	$277.2M	↑ 19.36%
Net Income	$27.3M	↓ 527.44%
Net Profit Margin	9.85%	↑ 12.6%

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

	Q2 FY24	Q/Q Change
Revenue	$73.8M	↑ 45.29%
Net Income	$11.4M	↓ 230.56%
Net Profit Margin	15.43%	↑ 32.6%

	Q3 FY24	Q/Q Change
Revenue	$80.6M	↑ 9.26%
Net Income	$17.6M	↑ 54.52%
Net Profit Margin	21.82%	↑ 6.39%

	Q4 FY24	Q/Q Change
Revenue	$72.0M	↓ 10.66%
Net Income	$7.1M	↓ 59.93%
Net Profit Margin	9.79%	↓ 12.03%

	Q1 FY25	Q/Q Change
Revenue	$68.2M	↓ 5.37%
Net Income	$-96.1M	↓ 1463.11%
Net Profit Margin	-140.98%	↓ 150.77%

	Q2 FY25	Q/Q Change
Revenue	$95.4M	↑ 40.02%
Net Income	$18.7M	↓ 119.48%
Net Profit Margin	19.62%	↑ 160.6%

	Q3 FY25	Q/Q Change
Revenue	$94.9M	↓ 0.59%
Net Income	$26.9M	↑ 43.83%
Net Profit Margin	28.38%	↑ 8.76%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$15.8M	↓ 216.41%

	FY20	Y/Y Change
Profit	$32.6M	↑ 106.2%

	FY21	Y/Y Change
Profit	$265.9M	↑ 714.53%

	FY22	Y/Y Change
Profit	$460.5M	↑ 73.22%

	FY23	Y/Y Change
Profit	$182.1M	↓ 60.45%

	FY24	Y/Y Change
Profit	$227.8M	↑ 25.08%

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

	Q2 FY24	Q/Q Change
Profit	$61.8M	↑ 55.21%

	Q3 FY24	Q/Q Change
Profit	$67.5M	↑ 9.28%

	Q4 FY24	Q/Q Change
Profit	$58.6M	↓ 13.21%

	Q1 FY25	Q/Q Change
Profit	$54.4M	↓ 7.21%

	Q2 FY25	Q/Q Change
Profit	$81.4M	↑ 49.66%

	Q3 FY25	Q/Q Change
Profit	$80.5M	↓ 1.15%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-121.3M	↓ 7.65%
Investing Cash Flow	$-42.8M	↓ 177.13%
Financing Cash Flow	$154.4M	↑ 55.8%

	FY20	Y/Y Change
Operating Cash Flow	$-92.3M	↓ 23.92%
Investing Cash Flow	$-26.5M	↓ 37.98%
Financing Cash Flow	$109.5M	↓ 29.06%

	FY21	Y/Y Change
Operating Cash Flow	$335.5M	↓ 463.71%
Investing Cash Flow	$14.2M	↓ 153.61%
Financing Cash Flow	$55.8M	↓ 49.06%

	FY22	Y/Y Change
Operating Cash Flow	$62.7M	↓ 81.31%
Investing Cash Flow	$-316.0M	↓ 2321.41%
Financing Cash Flow	$19.5M	↓ 64.99%

	FY23	Y/Y Change
Operating Cash Flow	$100.6M	↑ 60.35%
Investing Cash Flow	$-153.9M	↓ 51.29%
Financing Cash Flow	$1.4M	↓ 92.9%

	FY24	Y/Y Change
Operating Cash Flow	$66.5M	↓ 33.86%
Investing Cash Flow	$-18.0M	↓ 88.28%
Financing Cash Flow	$-102.0M	↓ 7460.53%

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

	Q2 FY24	Q/Q Change
Operating Cash Flow	$10.7M	↓ 164.23%
Investing Cash Flow	$-28.8M	↓ 1116.14%
Financing Cash Flow	$-1.4M	↓ 66.33%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$19.5M	↑ 81.71%
Investing Cash Flow	$-15.5M	↓ 46.24%
Financing Cash Flow	$2.5M	↓ 274.98%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$53.0M	↑ 172.31%
Investing Cash Flow	$23.4M	↓ 251.09%
Financing Cash Flow	$-98.9M	↓ 4093.34%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-19.6M	↓ 137.05%
Investing Cash Flow	$6.9M	↓ 70.43%
Financing Cash Flow	$-31.9M	↓ 67.76%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$23.4M	↓ 219.31%
Investing Cash Flow	$94.8M	↑ 1271.81%
Financing Cash Flow	$-71.9M	↑ 125.58%

	Q3 FY25	Q/Q Change
Operating Cash Flow	$33.8M	↑ 44.38%
Investing Cash Flow	$27.3M	↓ 71.18%
Financing Cash Flow	$-61.0K	↓ 99.92%

About Dynavax Technologies Corporation

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Organization	Dynavax Technologies Corporation
Employees	405
CEO	Mr. Ryan Spencer
Industry	Health Technology

Key Management of Dynavax Technologies Corporation

Name	Title
Mr. Ryan Spencer	CEO & Director
Ms. Kelly MacDonald CPA	Senior VP & CFO
Mr. David F. Novack	Senior VP & COO
Mr. John L. Slebir Esq.	Senior VP & General Counsel
Dr. Robert Janssen M.D.	Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs
Mr. Joseph Metzinger	VP & Chief Accounting Officer
Mr. Jeff P. Coon	Senior VP & Chief Human Resources Officer
Mr. Paul Cox	VP of Investor Relations & Corporate Communications
Mr. Donn Casale	Senior VP & Chief Commercial Officer
Dr. Dong Yu	Senior Vice President of Research

Important FAQs about investing in DVAX Stock from India :

What is Dynavax Technologies Corporation share price today?

Dynavax Technologies Corporation share price today is $15.50 as on February 9, 2026 at 12:00 am IST at the close of the market. Dynavax Technologies Corporation share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Dynavax Technologies Corporation share?

Dynavax Technologies Corporation share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Dynavax Technologies Corporation stock price today i.e. February 9, 2026 at 12:00 am IST is closed at $15.50, lower by 1.46% versus the 52 week high.

How to invest in Dynavax Technologies Corporation Stock (DVAX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Dynavax Technologies Corporation on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Dynavax Technologies Corporation Shares that will get you 0.0968 shares as per Dynavax Technologies Corporation share price of $15.50 per share as on February 9, 2026 at 12:00 am IST.

What is the minimum amount required to buy Dynavax Technologies Corporation Stock (DVAX) from India?

Indian investors can start investing in Dynavax Technologies Corporation (DVAX) shares with as little as ₹94.49 or $1 (as of June 26, 2026) using the INDmoney app.
For example: If you want to invest $10 or ₹944.90 in Dynavax Technologies Corporation stock (as per the Rupee-Dollar exchange rate as on June 26, 2026). Based on Dynavax Technologies Corporation share’s latest price of $15.50 as on February 9, 2026 at 12:00 am IST, you will get 0.6452 shares of Dynavax Technologies Corporation. Learn more about fractional shares .

What are the returns that Dynavax Technologies Corporation has given to Indian investors in the last 5 years?

Dynavax Technologies Corporation stock has given 0.0% share price returns and 27.31% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?

Discover More

Chain Bridge I
$3.52
-15.18%
Functional Brands, Inc. Common Stock
$0.01
+0.0%
Sleep Number Corporation Common Stock
$0.12
-42.86%
PNC Financial Services Group
$244.89
+2.07%
JPMorgan BetaBuilders U.S. Equity ETF
$132.01
-0.08%
First Trust Capital Strength ETF
$93.23
-0.7%
GraniteShares ETF Trust GraniteShares 2x Long TSLA Daily ETF
$19.52
-0.31%
American Century Large Cap Growth ETF
$66.98
-0.62%
Virtus InfraCap U.S. Preferred Stock ETF
$20.52
-1.06%

Explore all